Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters











Publication year range
2.
Clin Geriatr Med ; 40(1): 25-36, 2024 02.
Article in English | MEDLINE | ID: mdl-38000861

ABSTRACT

Skin cancers are the most common malignancies to affect older adults. The most common skin cancers, basal and squamous cell carcinoma, can usually be cured with surgery. Although less common, melanoma can be deadly when not caught in its earliest stages.


Subject(s)
Carcinoma, Basal Cell , Carcinoma, Squamous Cell , Melanoma , Skin Neoplasms , Humans , Aged , Mohs Surgery , Skin Neoplasms/diagnosis , Skin Neoplasms/therapy , Skin Neoplasms/pathology , Melanoma/diagnosis , Melanoma/therapy , Melanoma/pathology , Carcinoma, Squamous Cell/therapy , Carcinoma, Squamous Cell/surgery , Carcinoma, Basal Cell/surgery
4.
Dermatitis ; 33(5): 337-340, 2022.
Article in English | MEDLINE | ID: mdl-34570013

ABSTRACT

BACKGROUND: Patch testing is the standard to diagnose allergic contact dermatitis (ACD). OBJECTIVE: This study assessed the value of patch testing for product changes and quality of life in children with ACD. METHODS: In this cross-sectional survey, we used a questionnaire to follow up with families of ACD patients about changes since patch testing and counseling preferences. Eligible participants were 18 years or younger during expanded series or personalized patch tests at the Washington University School of Medicine from 2007 to 2020. RESULTS: Of the 43 enrolled participants, most were positive for multiple allergens (63%) and changed personal products after patch testing (71%). Only 26% of the families consistently read product labels before patch testing, compared with 66% after. Patients saw a mean relative reduction of 49% in severity of rash (8.2-4.2 of 10), 46% in interference with activities (5.7-3.1), and 51% in self-consciousness (7.0-3.4) since patch testing. Families gave favorable feedback for counseling on products to avoid (9.4 of 10 average rating of usefulness), product recommendations (8.5 of 10), and chemical names (7.9 of 10). CONCLUSIONS: Patch testing can lead to meaningful improvements in quality of life for most children with ACD. Counseling related to positive patch test results should include discussion of specific products to use and avoid.


Subject(s)
Dermatitis, Allergic Contact , Quality of Life , Allergens , Child , Cross-Sectional Studies , Dermatitis, Allergic Contact/diagnosis , Dermatitis, Allergic Contact/etiology , Follow-Up Studies , Humans , Patch Tests/methods , Surveys and Questionnaires
5.
J Cutan Pathol ; 48(3): 439-450, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33617128

ABSTRACT

Within the literature, there is overlap in the histopathological features described in eosinophilic folliculitis associated with chronic lymphocytic leukemia (CLL), eosinophilic dermatosis of hematologic malignancy, and acneiform follicular mucinosis. These disorders are described with varying degrees of superficial and deep lymphocytic and eosinophilic inflammation demonstrating perivascular, perifollicular, and folliculocentric involvement with or without follicular mucin deposition. Given significant histopathological overlap, these diagnoses may represent a continuum on a spectrum of dermatoses. Here, we present two cases with histopathological elements that reflect components of this clinicopathological spectrum and compare our findings with previously reported cases to compare and contrast reported features. Our first case is a 71-year-old African American man with long-standing CLL who developed a pruritic erythematous papular eruption on the face and chest with biopsy revealing a dense folliculotropic lymphocytic infiltrate with conspicuous eosinophils and follicular mucinosis. Our second case is a 70-year-old Caucasian man recently diagnosed with CLL/small lymphocytic lymphoma who developed an erythematous papular rash on the neck and face with biopsy revealing superficial and deep perivascular and periadnexal lymphocytic inflammation with scattered eosinophils. Characterization of our two cases and comparison with available literature suggest that these disorders may represent a continuum of dermatoses.


Subject(s)
Eosinophilia/pathology , Eosinophils/pathology , Folliculitis/pathology , Hematologic Neoplasms/pathology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Lymphoma, T-Cell, Cutaneous/pathology , Mucinosis, Follicular/pathology , Skin Diseases, Vesiculobullous/pathology , Skin Diseases/pathology , Acneiform Eruptions/pathology , Administration, Topical , Adrenal Cortex Hormones/administration & dosage , Adrenal Cortex Hormones/therapeutic use , Adult , Aged , Aged, 80 and over , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/therapeutic use , Biopsy , Diagnosis, Differential , Eosinophilia/drug therapy , Folliculitis/drug therapy , Hematologic Neoplasms/complications , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Lymphoma, T-Cell, Cutaneous/complications , Male , Middle Aged , Mucinosis, Follicular/drug therapy , Prednisone/administration & dosage , Prednisone/therapeutic use , Skin Diseases/drug therapy , Skin Diseases/immunology , Skin Diseases, Vesiculobullous/drug therapy , Treatment Outcome
6.
Dermatitis ; 31(2): 144-146, 2020.
Article in English | MEDLINE | ID: mdl-31441780

ABSTRACT

BACKGROUND: Epicutaneous patch testing was developed as a simple and effective method for diagnosing allergic contact dermatitis (ACD). Despite its proven value in ACD diagnoses, there is no defined standard for patch testing in children. OBJECTIVE: The aims of this study were to assess patch test positivity in pediatric patients with and without a history of atopic dermatitis suspected to have ACD, to compare these results with what the Thin-Layer Rapid Use Epicutaneous (T.R.U.E.) Test would have captured, and to evaluate likely exposures. METHODS: Pediatric patients receiving a North American 80 Comprehensive Series patch test or a personalized patch test were analyzed for allergen sensitization 48 to 72 hours after patch removal. These data were analyzed for allergen inclusion in the North American 80 Comprehensive Series patch test compared with the T.R.U.E. Test, as well as compared with patients with and without a history of atopic dermatitis. RESULTS: Of the 29 patients (mean ± SD age = 10.9 ± 5.1 years), 25 children demonstrated at least 1 positive reaction, with a total of 81 reactions overall. 40 (49.4%) of the reactions came from allergens outside of the T.R.U.E. Test, including cocamidopropyl betaine, which was frequent in patients with atopic dermatitis. CONCLUSIONS: Expanded and personalized patch tests provide a more comprehensive allergen inventory than the traditional T.R.U.E. Test. Pediatric patients frequently have reactions to allergens not included in the T.R.U.E. Test, and these allergens are commonly found in household products. Cocamidopropyl betaine was a particularly relevant allergen in our population. Expanded series patch testing and appropriate counseling should be provided to pediatric patients with ACD.


Subject(s)
Allergens/adverse effects , Dermatitis, Allergic Contact/diagnosis , Patch Tests/methods , Adolescent , Child , Child, Preschool , Dermatitis, Allergic Contact/etiology , Dermatitis, Atopic/complications , Female , Humans , Male , Retrospective Studies
7.
J Cutan Pathol ; 47(3): 263-268, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31587324

ABSTRACT

Metastatic carcinoma to the skin occurs in only a minority of patients with a visceral or internal malignancy, with breast, lung, and colorectum accounting for the majority of cases. We present the case of a 66-year-old man with a recent violaceous nodule of the left scalp (1.2 × 1.0 × 0.2 cm) that was a metastatic pancreatic adenosquamous carcinoma, representing a seemingly rare event. Two months prior, after complaining of right hip pain, an image revealed a right femoral lesion. A biopsy of that lesion showed moderately differentiated adenocarcinoma. Subsequent imaging showed a mass in the pancreatic tail and also markedly elevated serum tumor markers, CA 19-9 and carcinoembryonic antigen (5325 and 111.5 U/mL, respectively). Before the appearance of the scalp nodule, the patient received radiotherapy and was started on chemotherapy, which was continued after diagnosis and resection of the nodule. Subsequent metastases developed in the liver, lung and additional cutaneous lesions. He died 11 months after initial presentation with right hip pain. As this case shows, cutaneous metastases confer a poor prognosis, often with less than a year survival following their appearance.


Subject(s)
Carcinoma, Adenosquamous/secondary , Head and Neck Neoplasms/secondary , Pancreatic Neoplasms/pathology , Scalp/pathology , Skin Neoplasms/secondary , Aged , Fatal Outcome , Humans , Male , Pancreatic Neoplasms
9.
BMJ Case Rep ; 20182018 Mar 05.
Article in English | MEDLINE | ID: mdl-29507011

ABSTRACT

Extramammary Paget's disease (EMPD) is a rare intraepithelial neoplasm with an extremely variable clinical course. The objective of this study was to determine if combination imiquimod and photodynamic therapy could induce remission of EMPD. A 69-year-old man with EMPD was treated with topical imiquimod 5% cream at night for 5 days per week for 1 month, followed by 2 months of 5% imiquimod for three nights a week. For the following 6 months, monthly 5-aminolevulinic acid photodynamic therapy was added. After 6 months, imiquimod was discontinued and the patient continued to be treated with quarterly photodynamic therapy. Treatment resulted in significant improvement in the appearance of the lesion, and pathology revealed no evidence of residual disease. The patient has had no clinical signs of disease for >5 years. We conclude that topical imiquimod 5% cream and photodynamic therapy may aid in the treatment of some patients with EMPD.


Subject(s)
Aminoquinolines/administration & dosage , Antineoplastic Agents/administration & dosage , Genital Neoplasms, Male/drug therapy , Paget Disease, Extramammary/drug therapy , Photochemotherapy , Administration, Topical , Aged , Aminolevulinic Acid/administration & dosage , Biopsy , Genital Neoplasms, Male/pathology , Humans , Imiquimod , Male , Paget Disease, Extramammary/pathology , Photosensitizing Agents/administration & dosage , Scrotum/pathology
11.
J Clin Invest ; 124(11): 5037-41, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25295539

ABSTRACT

Allergic contact dermatitis (ACD) is well recognized as an adverse event associated with implantable medical devices that contain allergenic materials like nickel; however, other cutaneous consequences of chronic exposure to allergens in implanted devices are not well understood. Here, we present a clinical case of Marjolin's ulcer, an invasive squamous cell carcinoma (SCC) that developed in response to chronic ACD caused by an orthopedic implant. We used a standard murine model of contact hypersensitivity to determine whether chronic ACD promotes skin carcinogenesis. Chronic application of 1-fluoro-2,4-dinitrobenzene (DNFB) to carcinogen-treated skin led to the development of papillomas and aggressive SCC. DNFB-driven chronic ACD was marked by type 2 inflammation, which mediated skin carcinogenesis, as mice unable to mount an inflammatory response were less likely to develop skin tumors. Importantly, we found similar tumor-promoting inflammation surrounding the SCC in our patient. Our findings demonstrate that chronic ACD caused by constant exposure to an allergen can promote tumorigenesis at skin sites with preexisting cancer-initiated cells. Moreover, our results suggest that patients with implantable devices placed in close proximity to the skin should be monitored for ACD and highlight the importance of patch testing prior to the placement of such devices.


Subject(s)
Carcinoma, Squamous Cell/diagnosis , Dermatitis, Allergic Contact/complications , Skin Neoplasms/diagnosis , Animals , Carcinogenesis/immunology , Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/surgery , Chronic Disease , Dermatitis, Allergic Contact/pathology , Female , Humans , Internal Fixators/adverse effects , Mice, Inbred C57BL , Middle Aged , Nickel/immunology , Skin Neoplasms/immunology , Skin Neoplasms/surgery
12.
Dermatol Online J ; 19(1): 12, 2013 Jan 15.
Article in English | MEDLINE | ID: mdl-23374954

ABSTRACT

With Roche's withdrawl of Accutane from the U.S. market in 2009, isotretinoin has only been available in its generic form. Many clinicians fail to realize that for approval by the U.S. Food and Drug Administration, a generic medication must have a bioequivalence between 80 percent and 125 percent of that of the innovator product. This potential variability in bioavailability between branded and generic medications is important to keep in mind with isotretinoin, given the implications for achieving a sustained remission in acne patients.


Subject(s)
Acne Vulgaris/drug therapy , Drugs, Generic/administration & dosage , Isotretinoin/administration & dosage , Drugs, Generic/standards , Humans , Therapeutic Equivalency
13.
J Am Acad Dermatol ; 65(4): 855-862, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21550134

ABSTRACT

BACKGROUND: Angioimmunoblastic T-cell lymphoma (AITL) accounts for 18% of peripheral T-cell lymphomas worldwide. Skin involvement occurs in up to 50% of patients but poses a diagnostic dilemma because of the limited number of reported cases and subsequent lack of established diagnostic criteria. OBJECTIVE: The purpose of this review is to examine common clinical, histologic, and molecular findings in cases of AITL with the hope of improving the diagnostic accuracy of this challenging condition. METHODS: We present a case of AITL and conducted a review of the literature. RESULTS: The common clinical and histologic features in cases of AITL are nonspecific. However, newer immunohistochemical stains and gene rearrangement studies appear very promising at improving diagnostic capabilities. LIMITATIONS: There was a paucity of reported cases of AITL in the literature, and this review is retrospective. CONCLUSION: AITL presents with nonspecific clinical and histologic findings, but immunohistochemical stains and gene rearrangements can help establish the diagnosis.


Subject(s)
Immunoblastic Lymphadenopathy/pathology , Lymphoma, T-Cell, Cutaneous/pathology , Skin Neoplasms/pathology , Aged , Arthralgia/diagnosis , Arthralgia/pathology , Cyclophosphamide/administration & dosage , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Diphtheria Toxin/therapeutic use , Doxorubicin/administration & dosage , Epstein-Barr Virus Infections/diagnosis , Epstein-Barr Virus Infections/pathology , Gene Rearrangement, T-Lymphocyte , Humans , Immunoblastic Lymphadenopathy/diagnosis , Immunoblastic Lymphadenopathy/therapy , Immunoblastic Lymphadenopathy/virology , Interleukin-2/therapeutic use , Lymphoma, T-Cell, Cutaneous/diagnosis , Lymphoma, T-Cell, Cutaneous/therapy , Lymphoma, T-Cell, Cutaneous/virology , Male , Methotrexate/administration & dosage , Prednisolone/administration & dosage , Pruritus/diagnosis , Recombinant Fusion Proteins/therapeutic use , Retrospective Studies , Skin Neoplasms/diagnosis , Skin Neoplasms/therapy , Skin Neoplasms/virology , Stem Cell Transplantation , Vinblastine/administration & dosage , Vinblastine/analogs & derivatives , Vincristine/administration & dosage , Vinorelbine , Gemcitabine
SELECTION OF CITATIONS
SEARCH DETAIL